Current and future developments in travelers’ diarrhea therapy

References

• DuPont AW, DuPont HL. Travelers’ diarrhea: modern concepts and new developments. Curr. Treat. Options Gastroenterol.9(1), 13–21 (2006).
   PubMedGoogle Scholar
• DuPont H. Travelers’ diarrhea: antimicrobial therapy and chemoprevention. Nature Clin. Pract. Gastroenterol. Hepatol.2, 191–198 (2005).
   PubMedGoogle Scholar
• Al-Abri SS, Beeching NJ, Nye FJ. Traveller’s diarrhoea. Lancet Infect. Dis.5(6), 349–360 (2005).
   PubMed Web of Science ®Google Scholar
• Adachi JA, Jiang ZD, Mathewson JJ et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin. Infect. Dis.32(12), 1706–1709 (2001).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Lowe B, Verenkar MP et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis.185(4), 497–502 (2002).
   PubMed Web of Science ®Google Scholar
• Echeverria P, Sack RB, Blacklow NR, Bodhidatta P, Rowe B, McFarland A. Prophylactic doxycycline for travelers’ diarrhea in Thailand. Further supportive evidence of Aeromonas hydrophila as an enteric pathogen. Am. J. Epidemiol.120(6), 912–921 (1984).
   PubMed Web of Science ®Google Scholar
• Sriratanaban A, Reinprayoon S. Vibrio parahaemolyticus: a major cause of travelers’ diarrhea in Bangkok. Am. J. Trop. Med. Hyg.31(1), 128–130 (1982).
   PubMed Web of Science ®Google Scholar
• Ko G, Garcia C, Jiang ZD et al. Noroviruses as a cause of traveler’s diarrhea among students from the United States visiting Mexico. J. Clin. Microbiol.43(12), 6126–6129 (2005).
   PubMed Web of Science ®Google Scholar
• Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J. Infect. Dis.191(7), 1050–1055 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson JM, Smith KE, Vugia DJ et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J. Infect. Dis.190(6), 1150–1157 (2004).
   PubMed Web of Science ®Google Scholar
• Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin. Infect. Dis.26(2), 341–345 (1998).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Haynes GA, Pickering LK, Tjoa W, Sullivan P, Olarte J. Diarrhea of travelers to Mexico. Relative susceptibility of United States and Latin American students attending a Mexican University. Am. J. Epidemiol.105(1), 37–41 (1977).
   PubMed Web of Science ®Google Scholar
• Steffen R. Epidemiologic studies of travelers’ diarrhea, severe gastrointestinal infections, and cholera. Rev. Infect. Dis.8(Suppl. 2), S122–S130 (1986).
   PubMedGoogle Scholar
• Steffen R, van der Linde F, Gyr K, Schar M. Epidemiology of diarrhea in travelers. JAMA249(9), 1176–1180 (1983).
   PubMed Web of Science ®Google Scholar
• Glass RI, Holmgren J, Haley CE et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol.121(6), 791–796 (1985).
   PubMed Web of Science ®Google Scholar
• Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol.79(11), 6714–6722 (2005).
   PubMed Web of Science ®Google Scholar
• Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J. Med. Virol.77(1), 116–120 (2005).
   PubMed Web of Science ®Google Scholar
• Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis.185(9), 1335–1337 (2002).
   PubMed Web of Science ®Google Scholar
• Greenberg DE, Jiang ZD, Steffen R, Verenker MP, DuPont HL. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J. Infect. Dis.185(7), 944–949 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Okhuysen PC, Guo DC et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J. Infect. Dis.188(4), 506–511 (2003).
   PubMed Web of Science ®Google Scholar
• Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. Br. Med. J.312(7028), 414–415 (1996).
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, Hornick RB. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J. Infect. Dis.129(1), 45–52 (1974).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Formal SB, Hornick RB et al. Pathogenesis of Escherichia coli diarrhea. N. Engl. J. Med.285(1), 1–9 (1971).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann. Intern. Med.142(10), 805–812 (2005).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, Patterson TF, DuPont HL. Clinical presentation as a guide to therapy for travelers’ diarrhea. Am. J. Med. Sci.294(2), 91–96 (1987).
   PubMed Web of Science ®Google Scholar
• Haberberger RL Jr, Mikhail IA, Burans JP et al. Travelers’ diarrhea among United States military personnel during joint American–Egyptian armed forces exercises in Cairo, Egypt. Mil. Med.156(1), 27–30 (1991).
   PubMed Web of Science ®Google Scholar
• Mattila L. Clinical features and duration of traveler’s diarrhea in relation to its etiology. Clin. Infect. Dis.19(4), 728–734 (1994).
   PubMed Web of Science ®Google Scholar
• von Sonnenburg F, Tornieporth N, Waiyaki P et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet356(9224), 133–134 (2000).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin. Infect. Dis.22(1), 124–128 (1996).
   PubMed Web of Science ®Google Scholar
• Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am. J. Gastroenterol.99(9), 1774–1778 (2004).
   PubMed Web of Science ®Google Scholar
• Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut52(4), 523–526 (2003).
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology125(6), 1651–1659 (2003).
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol.98(7), 1578–1583 (2003).
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, DuPont HL. Bacterial overgrowth syndrome after acute nonspecific diarrhoea. Lancet1(8059), 337–338 (1978).
   PubMed Web of Science ®Google Scholar
• Brunser O, Eidelman S, Klipstein FA. Intestinal morphology of rural Haitians. A comparison between overt tropical sprue and asymptomatic subjects. Gastroenterology58(5), 655–668 (1970).
   PubMed Web of Science ®Google Scholar
• Landzberg BR, Connor BA. Persistent diarrhea in the returning traveler: think beyond persistent infection. Scand. J. Gastroenterol.40(1), 112–114 (2005).
   PubMed Web of Science ®Google Scholar
• Yanai-Kopelman D, Paz A, Rippel D, Potasman I. Inflammatory bowel disease in returning travelers. J. Travel Med.7(6), 333–335 (2000).
   PubMed Web of Science ®Google Scholar
• Connor BA. Sequelae of traveler’s diarrhea: focus on postinfectious irritable bowel syndrome. Clin. Infect. Dis.41(Suppl. 8), S577–S586 (2005).
   Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ, de la Cabada FJ, Conrad DA. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA267(14), 1932–1935 (1992).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW. Five versus three days of ofloxacin therapy for traveler’s diarrhea: a placebo-controlled study. Antimicrob. Agents Chemother.36(1), 87–91 (1992).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N. Engl. J. Med.307(14), 841–844 (1982).
   PubMed Web of Science ®Google Scholar
• Gomi H, Jiang ZD, Adachi JA et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob. Agents Chemother.45(1), 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler’s diarrhea. J. Travel Med.4(1), 3–7 (1997).
   PubMedGoogle Scholar
• Ericsson CD, Johnson PC, DuPont HL, Morgan DR, Bitsura JA, de la Cabada FJ. Ciprofloxacin or trimethoprim–sulfamethoxazole as initial therapy for travelers’ diarrhea. A placebo-controlled, randomized trial. Ann. Intern. Med.106(2), 216–220 (1987).
   PubMed Web of Science ®Google Scholar
• Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers’ diarrhoea. Lancet344(8936), 1537–1539 (1994).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers’ diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann. Intern. Med.114(9), 731–734 (1991).
   PubMed Web of Science ®Google Scholar
• Kuschner RA, Trofa AF, Thomas RJ et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis.21(3), 536–541 (1995).
   PubMed Web of Science ®Google Scholar
• DuPont HL. Antimicrobial-resistant Campylobacter species – a new threat to travelers to Thailand. Clin. Infect. Dis.21(3), 542–543 (1995).
   PubMed Web of Science ®Google Scholar
• Gaunt PN, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J. Antimicrob. Chemother.37(4), 747–757 (1996).
   PubMed Web of Science ®Google Scholar
• Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982–2001. Emerg. Infect. Dis.8(12), 1501–1503 (2002).
   PubMed Web of Science ®Google Scholar
• Smith KE, Besser JM, Hedberg CW et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N. Engl. J. Med.340(20), 1525–1532 (1999).
   PubMed Web of Science ®Google Scholar
• Krausse R, Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob. Agents Chemother.47(9), 2946–2950 (2003).
   PubMed Web of Science ®Google Scholar
• Adachi JA, Ericsson CD, Jiang Z-Det al. Azithromycin is comparable to levofloxacin in the treatment of U.S. travelers with acute diarrhea acquired in Mexico. Clin. Infect. Dis.37, 1165–1171 (2003).
   Google Scholar
• Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis.16(2), 111–118 (1993).
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother.44(8), 2205–2206 (2000).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion59(6), 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis.33(11), 1807–1815 (2001).
   PubMed Web of Science ®Google Scholar
• Steffen R, Sack DA, Riopel L et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am. J. Gastroenterol.98(5), 1073–1078 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor D, Bourgeois A, Ericsson C et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am. J. Trop. Med. Hyg. (2006) (In press).
   Google Scholar
• Malvisi Stracciari J, Venturini AP, Anfossi P, Marchi E, Stracciari GL. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia6(2), 82–84 (1987).
   PubMedGoogle Scholar
• Soro O, Pesce A, Raggi M, Debbia EA, Schito GC. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin. Microbiol. Infect.3(1), 147–151 (1997).
   PubMedGoogle Scholar
• Portnoy BL, DuPont HL, Pruitt D, Abdo JA, Rodriguez JT. Antidiarrheal agents in the treatment of acute diarrhea in children. JAMA236(7), 844–846 (1976).
   PubMed Web of Science ®Google Scholar
• Reves R, Bass P, DuPont HL, Sullivan P, Mendiola J. Failure to demonstrate effectiveness of an anticholinergic drug in the symptomatic treatment of acute travelers’ diarrhea. J. Clin. Gastroenterol.5(3), 223–237 (1983).
   PubMed Web of Science ®Google Scholar
• Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology86(6), 1475–1480 (1984).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA226(13), 1525–1528 (1973).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology73(4 Pt 1), 715–718 (1977).
   PubMed Web of Science ®Google Scholar
• Powell DW, Tapper EJ, Morris SM. Aspirin-stimulated intestinal electrolyte transport in rabbit ileum in vitro. Gastroenterology76(6), 1429–1437 (1979).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Flores Sanchez J, Ericsson CD et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am. J. Med.88(6A), 15S–19S (1990).
   Google Scholar
• Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers’ diarrhea. JAMA255(6), 757–760 (1986).
   PubMed Web of Science ®Google Scholar
• Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N. Engl. J. Med.343(7), 463–467 (2000).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Ericsson CD, Mathewson JJ, Marani S, Knellwolf-Cousin AL, Martinez-Sandoval FG. Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers’ diarrhea. Gastroenterology104(3), 709–715 (1993).
   PubMed Web of Science ®Google Scholar
• DiCesare D, DuPont HL, Mathewson JJ et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am. J. Gastroenterol.97(10), 2585–2588 (2002).
   PubMed Web of Science ®Google Scholar
• Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand. J. Gastroenterol.37(6), 656–661 (2002).
   PubMed Web of Science ®Google Scholar
• Okhuysen PC, DuPont HL, Ericsson CD et al. Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler’s diarrhea: randomized, placebo-controlled trial. Clin. Infect. Dis.21(2), 341–344 (1995).
   PubMed Web of Science ®Google Scholar
• Siberschmidt G, Schick MT, Steffen R et al. Treatment of travellers’ diarrhoea: zaldaride compared with loperamide and placebo. Eur. J. Gastroenterol. Hepatol.7, 871–875 (1995).
   PubMed Web of Science ®Google Scholar
• Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin. Infect. Dis.40(11), 1625–1634 (2005).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, DuPont HL, Okhuysen PC et al. Azithromycin (500 mg) plus loperamide effectively treats travelers’ diarrhea in Mexico. 9th Conference International Soc Travel Med. Lisbon, Portugal, May 2, Abstract FC01.10 (2005).
   Google Scholar
• Petruccelli BP, Murphy GS, Sanchez JL et al. Treatment of traveler’s diarrhea with ciprofloxacin and loperamide. J. Infect. Dis.165(3), 557–560 (1992).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Bodhidatta L, Echeverria P et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med.118(8), 582–586 (1993).
   PubMed Web of Science ®Google Scholar
• Caeiro JP, DuPont HL, Albrecht H, Ericsson CD. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler’s diarrhea. Clin. Infect. Dis.28(6), 1286–1289 (1999).
   PubMed Web of Science ®Google Scholar
• Kozicki M, Steffen R, Schar M. ‘Boil it, cook it, peel it or forget it’: does this rule prevent travellers’ diarrhoea? Int. J. Epidemiol.14(1), 169–172 (1985).
   PubMed Web of Science ®Google Scholar
• Bandres JC, Mathewson JJ, DuPont HL. Heat susceptibility of bacterial enteropathogens. Implications for the prevention of travelers’ diarrhea. Arch. Intern. Med.148(10), 2261–2263 (1988).
   PubMedGoogle Scholar
• Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler’s diarrhea. Clin. Infect. Dis.41(Suppl. 8), S531–S535 (2005).
   PubMed Web of Science ®Google Scholar
• Adachi JA, Mathewson JJ, Jiang ZD, Ericsson CD, DuPont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann. Intern. Med.136(12), 884–887 (2002).
   PubMed Web of Science ®Google Scholar
• Tjoa WS, DuPont HL, Sullivan P et al. Location of food consumption and travelers’ diarrhea. Am. J. Epidemiol.106(1), 61–66 (1977).
   PubMed Web of Science ®Google Scholar
• Wood LV, Ferguson LE, Hogan P et al. Incidence of bacterial enteropathogens in foods from Mexico. Appl. Environ. Microbiol.46(2), 328–332 (1983).
   PubMed Web of Science ®Google Scholar
• Kean BH, Waters S. The diarrhea of travelers. I. Incidence in travelers returning to the United States from Mexico. AMA Arch. Ind. Health.18(2), 148–150 (1958).
   PubMedGoogle Scholar
• Gorbach S, Edelman R. Travelers’ diarrhea: National Institutes of Health Consensus Development Conference. Rev. Infect. Dis.S209–S233 (1986).
   Google Scholar
• DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont MW, de la Cabada FJ. Prevention of travelers’ diarrhea by the tablet formulation of bismuth subsalicylate. JAMA257(10), 1347–1350 (1987).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Sullivan P, Evans DG et al. Prevention of traveler’s diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA243(3), 237–241 (1980).
   PubMed Web of Science ®Google Scholar
• Steffen R, DuPont HL, Heusser R et al. Prevention of traveler’s diarrhea by the tablet form of bismuth subsalicylate. Antimicrob. Agents Chemother.29(4), 625–627 (1986).
   PubMed Web of Science ®Google Scholar
• Ericsson CD, Feldman S, Pickering LK, Cleary TG. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA247(16), 2266–2267 (1982).
   PubMed Web of Science ®Google Scholar
• Kollaritsch H, Holst H, Grobara P, Wiedermann G. [Prevention of traveler’s diarrhea with Saccharomyces boulardii. results of a placebo controlled double-blind study]. Fortschr. Med.111(9), 152–156 (1993).
   PubMedGoogle Scholar
• Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J. Travel Med.4(1), 41–43 (1997).
   PubMedGoogle Scholar
• Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nature Med.6(3), 265–270 (2000).
   PubMed Web of Science ®Google Scholar
• Paton AW, Jennings MP, Morona R et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology128(5), 1219–1228 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson PC, Ericsson CD, Morgan DR, DuPont HL, Cabada FJ. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler’s diarrhea with norfloxacin. Antimicrob. Agents Chemother.30(5), 671–674 (1986).
   PubMed Web of Science ®Google Scholar
• Taylor DN, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic prevents shigellosis after experimental challenge. Clin. Infect. Dis.42(9), 1283–1288 (2006).
   PubMed Web of Science ®Google Scholar
• Boedeker EC. Vaccines for enterotoxigenic Escherichia coli: current status. Curr. Opin. Gastroenterol.21(1), 15–19 (2005).
   PubMed Web of Science ®Google Scholar
• Peltola H, Siitonen A, Kyronseppa H et al. Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet338(8778), 1285–1289 (1991).
   PubMed Web of Science ®Google Scholar
• Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine24(18), 3727–3734 (2005).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med.6(12), 1403–1406 (2000).
   PubMed Web of Science ®Google Scholar
• Ashley DV, Walters C, Dockery-Brown C, McNab A, Ashley DE. Interventions to prevent and control food-borne diseases associated with a reduction in traveler’s diarrhea in tourists to Jamaica. J. Travel Med.11(6), 364–367 (2004).
   PubMed Web of Science ®Google Scholar
• Steffen R, Collard F, Tornieporth N et al. Epidemiology, etiology, and impact of traveler’s diarrhea in Jamaica. JAMA281(9), 811–817 (1999).
   PubMed Web of Science ®Google Scholar